R. Mehta
25 Papers
95 Citations
R. Mehta is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 12 publications.
Chat about Author
Papers
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti,Edward Gane,Wai-Kay Seto,Henry Lik-Yuen Chan,Wan-Long Chuang,Tatjana Stepanova,Aric J. Hui,Young-Suk Lim,R. Mehta,Harry L. A. Janssen,Subrat K. Acharya,John F. Flaherty,Benedetta Massetto,Andrea L. Cathcart,Kyungpil Kim,Anuj Gaggar,G. Mani Subramanian,John G. McHutchison,Calvin Q. Pan,Maurizia Rossana Brunetto,Namiki Izumi,Patrick Marcellin +21 more
TL;DR: The primary efficacy endpoint was the proportion of patients who had HBV DNA less than 29 IU/mL at week 48 in those who received at least one dose of study drug; the study was powered to show non-inferiority with a 10% efficacy margin of tenofovir alafenamide compared with ten ofovir disoproxil fumarate.
487
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B
Patrick Marcellin,Sang Hoon Ahn,Wan-Lung Chuang,Aric J. Hui,Fehmi Tabak,R. Mehta,Jörg Petersen,Chuan-Mo Lee,Xiaoli Ma,F.A. Caruntu,Won Young Tak,Magdy Elkhashab,L. Lin,G. Wu,Eduardo B. Martins,Prista Charuworn,Leland J. Yee,Seng Gee Lim,Graham R. Foster,Scott Fung,L. Morano,Didier Samuel,Kosh Agarwal,Ramazan Idilman,Simone I. Strasser,Maria Buti,G. B. Gaeta,George V. Papatheodoridis,Robert Flisiak,Hung Chan +29 more
TL;DR: In patients with chronic hepatitis B, tenofovir disoproxil fumarate plus pegylated interferon for 48‐weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
36
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
Ajay Duseja,Shivaram Prasad Singh,Manu Mehta,Shalimar,Jayanthi Venkataraman,Varun Mehta,Krishnadas Devadas,Sanjib Kumar Kar,Omesh Goyal,Aabha Nagral,Sanjiv Saigal,Sandeep Nijhawan,Dibyalochan Praharaj,Akash Shukla,Brij Sharma,Krishnasamy Narayanasamy,Pramod Kumar,Padaki Nagaraja Rao,Anil Arora,R. Mehta,Pankaj Asati,Piyush Ranjan,Abraham Koshy,Seema Alam,Shrikant Mukewar,Saurabh Mukewar,V G Mohan Prasad,Mukul Rastogi,Arun J. Sanyal +28 more
TL;DR: Around one fifth of patients with NAFLD in South Asia have significant liver disease, and both hepatic and extrahepatic events on follow-up are observed more commonly in patients with nonalcoholic steatohepatitis-related compensated cirrhosis.
23
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Samir Shah,Abhijit Chowdhury,R. Mehta,Dharmesh Kapoor,Ajay Duseja,Abraham Koshy,Akash Shukla,Ajit Sood,Kaushal Madan,Randhir Sud,Sandeep Nijhawan,R. Pawan,Mohan Prasad,K. Kersey,Deyuan Jiang,Evguenia S. Svarovskaia,Brian P. Doehle,B. Kanwar,Mani Subramanian,Subrat K. Acharya,Shiv Kumar Sarin +20 more
TL;DR: Overall, sofosbuvir plus ribavirin therapy achieved SVR12 rates ≥90% and was well tolerated among treatment‐naïve patients with chronic genotype 1 or 3 HCV infection in India.
17